Pascal Odou
Overview
Explore the profile of Pascal Odou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
523
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bouchfaa M, Vasseur M, Courtin J, Pinturaud M, Beauval N, Allorge D, et al.
J Oncol Pharm Pract
. 2024 Aug;
:10781552241276530.
PMID: 39183571
Introduction: Many hospitals are now investing in robotic compounding system for the preparation of cytotoxic agents. The objective of the present study was to describe contamination by cytotoxics inside and...
12.
Lecoutre A, Vasseur M, Courtin J, Ben Othman S, Hammadi S, Pelayo S, et al.
Stud Health Technol Inform
. 2024 Aug;
316:1856-1860.
PMID: 39176853
Since March 2022, the centralized cytotoxic preparation unit at the Lille University Hospital (Lille, France) is equipped with augmented reality eyewear for preparation and quality control. The technology enables a...
13.
Moreau F, Decaudin B, Tod M, Odou P, Simon N
Eur J Hosp Pharm
. 2024 Aug;
PMID: 39137973
Objectives: Several drug-drug interaction (DDI) checkers such as DDI-Predictor have been developed to detect and grade DDIs. DDI-Predictor gives an estimate of the magnitude of an interaction based on the...
14.
Valentin B, Tchaparian M, Daran L, Fievet C, Odou P, Loiez C, et al.
Therapie
. 2024 Apr;
79(5):614-615.
PMID: 38599996
No abstract available.
15.
Leroy M, Desmedt E, Deramoudt L, Vasseur M, Odou P, Behal H, et al.
Melanoma Res
. 2024 Mar;
34(3):258-264.
PMID: 38489575
Nivolumab was first authorized at a weight-based dose (WBD) of 3 mg/kg every two weeks (Q2W). Since 2017, a fixed dose (FD) regimen [first 240 mg Q2W and then 480 ...
16.
Leroy M, Deramoudt L, Pinturaud M, Demaret J, Alidjinou E, Nudel M, et al.
Leuk Lymphoma
. 2024 Mar;
65(6):868-871.
PMID: 38440954
No abstract available.
17.
Ben Othman S, Decaudin B, Odou P, Rousseliere C, Cousein E, Hammadi S
Stud Health Technol Inform
. 2024 Mar;
310:1593-1597.
PMID: 38426884
The health product circuit corresponds to the chain of steps that a medicine goes through in hospital, from prescription to administration. The safety and regulation of all the stages of...
18.
Roche M, Rousseleau D, Danel C, Henry H, Lebuffe G, Odou P, et al.
Eur J Hosp Pharm
. 2024 Jan;
PMID: 38290833
Objectives: To assess the physicochemical stability of the combination of a propofol emulsion with an alpha-2 (α2) adrenergic receptor agonist (α2A; clonidine or dexmedetomidine) under conditions mimicking routine practice in...
19.
Cuvelier E, Khazri H, Lecluse C, Hennart B, Amad A, Roche J, et al.
Pharmaceuticals (Basel)
. 2024 Jan;
17(1).
PMID: 38256855
To avoid the failures in therapy with psychotropic drugs, treatments can be personalized by applying the results of therapeutic drug monitoring and pharmacogenetic testing. The objective of the present single-center...
20.
Durieux F, Dekyndt B, Legrand J, Rogeau A, Malek E, Semah F, et al.
Pharmaceuticals (Basel)
. 2023 Nov;
16(11).
PMID: 38004410
Prostate cancer is one of the most common forms of cancer in men. An imaging technique for its diagnosis is [Ga]-prostate-specific membrane antigen ([Ga]Ga-PSMA-11) positron emission tomography (PET). To address...